<?xml version='1.0' encoding='utf-8'?>
<document id="30529029"><sentence text="Lopinavir-ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir-ritonavir without rifampicin: a pharmacokinetic modelling and clinical study."><entity charOffset="0-19" id="DDI-PubMed.30529029.s1.e0" text="Lopinavir-ritonavir" /><entity charOffset="69-79" id="DDI-PubMed.30529029.s1.e1" text="rifampicin" /><entity charOffset="121-130" id="DDI-PubMed.30529029.s1.e2" text="lopinavir" /><entity charOffset="149-159" id="DDI-PubMed.30529029.s1.e3" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.30529029.s1.e0" e2="DDI-PubMed.30529029.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30529029.s1.e0" e2="DDI-PubMed.30529029.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30529029.s1.e0" e2="DDI-PubMed.30529029.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30529029.s1.e0" e2="DDI-PubMed.30529029.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30529029.s1.e1" e2="DDI-PubMed.30529029.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30529029.s1.e1" e2="DDI-PubMed.30529029.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30529029.s1.e1" e2="DDI-PubMed.30529029.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30529029.s1.e2" e2="DDI-PubMed.30529029.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30529029.s1.e2" e2="DDI-PubMed.30529029.s1.e3" /></sentence><sentence text="Rifampicin reduces lopinavir concentrations in HIV and tuberculosis co-treated patients"><entity charOffset="0-10" id="DDI-PubMed.30529029.s2.e0" text="Rifampicin" /><entity charOffset="19-28" id="DDI-PubMed.30529029.s2.e1" text="lopinavir" /><pair ddi="false" e1="DDI-PubMed.30529029.s2.e0" e2="DDI-PubMed.30529029.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30529029.s2.e0" e2="DDI-PubMed.30529029.s2.e1" /></sentence><sentence text=" We hypothesised that adding ritonavir to co-formulated lopinavir-ritonavir (4:1) to achieve a one-to-one ratio would overcome this drug-drug interaction in young children"><entity charOffset="29-38" id="DDI-PubMed.30529029.s3.e0" text="ritonavir" /><entity charOffset="56-65" id="DDI-PubMed.30529029.s3.e1" text="lopinavir" /><entity charOffset="66-75" id="DDI-PubMed.30529029.s3.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.30529029.s3.e0" e2="DDI-PubMed.30529029.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30529029.s3.e0" e2="DDI-PubMed.30529029.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30529029.s3.e0" e2="DDI-PubMed.30529029.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30529029.s3.e1" e2="DDI-PubMed.30529029.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30529029.s3.e1" e2="DDI-PubMed.30529029.s3.e2" /></sentence><sentence text="" /><sentence text="We did a prospective, open-label, one-group, one-sequence study at five sites in three South African provinces" /><sentence text=" We included HIV-infected children with tuberculosis, a bodyweight of 3-15 kg, and a post-conceptional age of more than 42 weeks" /><sentence text=" Children received the standard four-to-one ratio of lopinavir-ritonavir in the absence of rifampicin-based anti-tuberculosis treatment, whereas super-boosting of lopinavir-ritonavir with additional ritonavir was given orally twice a day to achieve a one-to-one ratio during rifampicin treatment"><entity charOffset="53-72" id="DDI-PubMed.30529029.s7.e0" text="lopinavir-ritonavir" /><entity charOffset="91-101" id="DDI-PubMed.30529029.s7.e1" text="rifampicin" /><entity charOffset="163-182" id="DDI-PubMed.30529029.s7.e2" text="lopinavir-ritonavir" /><entity charOffset="199-208" id="DDI-PubMed.30529029.s7.e3" text="ritonavir" /><entity charOffset="275-285" id="DDI-PubMed.30529029.s7.e4" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.30529029.s7.e0" e2="DDI-PubMed.30529029.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30529029.s7.e0" e2="DDI-PubMed.30529029.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30529029.s7.e0" e2="DDI-PubMed.30529029.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30529029.s7.e0" e2="DDI-PubMed.30529029.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30529029.s7.e0" e2="DDI-PubMed.30529029.s7.e4" /><pair ddi="false" e1="DDI-PubMed.30529029.s7.e1" e2="DDI-PubMed.30529029.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30529029.s7.e1" e2="DDI-PubMed.30529029.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30529029.s7.e1" e2="DDI-PubMed.30529029.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30529029.s7.e1" e2="DDI-PubMed.30529029.s7.e4" /><pair ddi="false" e1="DDI-PubMed.30529029.s7.e2" e2="DDI-PubMed.30529029.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30529029.s7.e2" e2="DDI-PubMed.30529029.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30529029.s7.e2" e2="DDI-PubMed.30529029.s7.e4" /><pair ddi="false" e1="DDI-PubMed.30529029.s7.e3" e2="DDI-PubMed.30529029.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30529029.s7.e3" e2="DDI-PubMed.30529029.s7.e4" /></sentence><sentence text=" The primary outcome was the comparison of the proportion of children with predicted lopinavir morning minimum concentrations (Cmin) of more than 1·0 mg/L during super-boosting with the proportion of more than 1·0 mg/L during standard lopinavir-ritonavir treatment without rifampicin"><entity charOffset="85-94" id="DDI-PubMed.30529029.s8.e0" text="lopinavir" /><entity charOffset="235-254" id="DDI-PubMed.30529029.s8.e1" text="lopinavir-ritonavir" /><entity charOffset="273-283" id="DDI-PubMed.30529029.s8.e2" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.30529029.s8.e0" e2="DDI-PubMed.30529029.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30529029.s8.e0" e2="DDI-PubMed.30529029.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30529029.s8.e0" e2="DDI-PubMed.30529029.s8.e2" /><pair ddi="false" e1="DDI-PubMed.30529029.s8.e1" e2="DDI-PubMed.30529029.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30529029.s8.e1" e2="DDI-PubMed.30529029.s8.e2" /></sentence><sentence text=" Lopinavir concentrations were determined before and at 1, 2, 4, 6, and 10 h after the morning dose during the second and the last month of tuberculosis co-treatment, and 4-6 weeks after stopping rifampicin"><entity charOffset="1-10" id="DDI-PubMed.30529029.s9.e0" text="Lopinavir" /><entity charOffset="196-206" id="DDI-PubMed.30529029.s9.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.30529029.s9.e0" e2="DDI-PubMed.30529029.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30529029.s9.e0" e2="DDI-PubMed.30529029.s9.e1" /></sentence><sentence text=" A non-linear mixed-effects model was implemented to interpret the data and Monte Carlo simulations were used to compare the percentage of lopinavir with morning Cmin values of less than 1·0 mg/L for the two dosing schemes"><entity charOffset="139-148" id="DDI-PubMed.30529029.s10.e0" text="lopinavir" /></sentence><sentence text=" A non-inferiority margin of 10% was used" /><sentence text=" This study is registered with ClinicalTrials" /><sentence text="gov, number NCT02348177" /><sentence text="" /><sentence text="Between Jan 30, 2013, and Nov 9, 2015, 96 children with a median age of 18·2 months (IQR 9·6-26·8) were enrolled" /><sentence text=" Of these 96 children, 80 (83%) completed the first three pharmacokinetic evaluations" /><sentence text=" Tuberculosis therapy was started before antiretrovirals in 70 (73%) children" /><sentence text=" The model-predicted percentage of morning Cmin of less than 1·0 mg/L after tuberculosis treatment without super-boosting was 8·8% (95% CI 0·6-19·8) versus 7·6% (0·4-16·2) during super-boosting and tuberculosis treatment" /><sentence text=" The difference of -1·1% (95% CI -6·9 to 3·2), at a non-inferiority margin of 10%, confirmed the non-inferiority of lopinavir trough concentrations during rifampicin co-treatment"><entity charOffset="116-125" id="DDI-PubMed.30529029.s19.e0" text="lopinavir" /><entity charOffset="155-165" id="DDI-PubMed.30529029.s19.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.30529029.s19.e0" e2="DDI-PubMed.30529029.s19.e0" /><pair ddi="false" e1="DDI-PubMed.30529029.s19.e0" e2="DDI-PubMed.30529029.s19.e1" /></sentence><sentence text=" 19 serious adverse events were reported in 12 participants" /><sentence text=" Three deaths and a temporary treatment interruption due to jaundice were unrelated to study treatment" /><sentence text="" /><sentence text="Lopinavir exposure with ritonavir super-boosting in a one-to-one ratio during rifampicin-based tuberculosis treatment was non-inferior to the exposure with lopinavir-ritonavir without rifampicin"><entity charOffset="0-9" id="DDI-PubMed.30529029.s23.e0" text="Lopinavir" /><entity charOffset="24-33" id="DDI-PubMed.30529029.s23.e1" text="ritonavir" /><entity charOffset="78-88" id="DDI-PubMed.30529029.s23.e2" text="rifampicin" /><entity charOffset="184-194" id="DDI-PubMed.30529029.s23.e3" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.30529029.s23.e0" e2="DDI-PubMed.30529029.s23.e0" /><pair ddi="false" e1="DDI-PubMed.30529029.s23.e0" e2="DDI-PubMed.30529029.s23.e1" /><pair ddi="false" e1="DDI-PubMed.30529029.s23.e0" e2="DDI-PubMed.30529029.s23.e2" /><pair ddi="false" e1="DDI-PubMed.30529029.s23.e0" e2="DDI-PubMed.30529029.s23.e3" /><pair ddi="false" e1="DDI-PubMed.30529029.s23.e1" e2="DDI-PubMed.30529029.s23.e1" /><pair ddi="false" e1="DDI-PubMed.30529029.s23.e1" e2="DDI-PubMed.30529029.s23.e2" /><pair ddi="false" e1="DDI-PubMed.30529029.s23.e1" e2="DDI-PubMed.30529029.s23.e3" /><pair ddi="false" e1="DDI-PubMed.30529029.s23.e2" e2="DDI-PubMed.30529029.s23.e2" /><pair ddi="false" e1="DDI-PubMed.30529029.s23.e2" e2="DDI-PubMed.30529029.s23.e3" /></sentence><sentence text=" Safe and effective, field application of super-boosting is limited by poor acceptability" /><sentence text=" Access to better adapted solid formulations will most likely facilitate public health implementation of this strategy" /><sentence text="" /><sentence text="DNDi, French Development Agency, UBS Optimus Foundation, and Unitaid" /><sentence text="" /></document>